What is the current stock price of Armata Pharmaceuticals, Inc. (ARMP)?

As of the latest market data, Armata Pharmaceuticals, Inc. (ARMP) is trading at $7.97. The stock has seen a loss of -2.45% today.

Does Armata Pharmaceuticals, Inc. (ARMP) pay a dividend?

Based on current data, Armata Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Armata Pharmaceuticals, Inc.?

The current market capitalization of Armata Pharmaceuticals, Inc. (ARMP) is approximately unavailable.

ARMP

Armata Pharmaceuticals, Inc.·Healthcare

7.97

2.448%(−0.20)

Close Price

8.20

2.886%(+0.23)

After Hours

Last Updated: — ET

52W L: $1.7452W H: $16.34

ARMP NEWS

prnewswire.com

May 13

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2026, and provided a corporate update. "Our top priority in 2026 is advancing Armata's lead Staphylococcus aureus ("S.

prnewswire.com

May 7

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02 on a faster path to potential approval and patient access LOS ANGELES, May 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to AP-SA02, the Company's intravenously administered Staphylococcus aureus ("S. aureus") multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S.

prnewswire.com

May 4

Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in Communications Biology, a peer-reviewed journal from Nature Portfolio. The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection," describes the structure of phage P7-1, which is included in Armata's multi-phage cocktail, AP-PA02.

prnewswire.com

Apr 27

Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.

LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Daniel B. Gilmer, Ph.D.

prnewswire.com

Mar 25

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Financial Results Grant Revenue.

prnewswire.com

Mar 19

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it will delay the announcement of its financial results for its fourth quarter and full-year ended December 31, 2025, and provided a corporate update. The Company requires additional time to complete its financial reporting and anticipates filing its Annual Report on Form 10-K on or before March 31, 2026, the due date.

Company Profile

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

1994-05-20

Beta

1.32

Websitewww.armatapharma.com↗